# A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

> **NCT04223804** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 41 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)
- HIV Infection
- HIV-1

## Interventions

- **DRUG:** ABBV-181
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04223804
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-30
- **Primary completion:** 2023-02-27
- **Final completion:** 2023-02-27
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223804, "A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04223804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*